Combination vaccine developed for smallpox and anthrax

October 6, 2010 by Lin Edwards, Medical Xpress report
Image credit: Wikipedia.

(PhysOrg.com) -- A new combination vaccine against both smallpox and anthrax has been tested in animal studies and found to be more effective against anthrax than the Emergent BioSolutions Inc. vaccine currently available.

The experimental vaccine, developed by scientists from the US (FDA) and the National Cancer Institute, was tested on rabbits and found to build up immunity to faster and more effectively than the anthrax-only vaccine, BioThrax, sold by Maryland company Emergent BioSolutions Inc., which is the version stockpiled by the US government.

The vaccine was developed from a version of Pfizer’s vaccination that had earlier been demonstrated to be more effective in mice with compromised immune systems. This modified vaccine was developed by National Cancer Institute researcher Liyanage Perera and colleagues by adding a gene to the vaccinia virus with a gene encoding for interleukin-15 (IL-15), which is a molecule that boosts the system and helps clear the smallpox virus from the system.

To this modified vaccine the researchers added a gene from the anthrax bacterium. The researchers say this may make the vaccine safer than the alternative because BioThrax contains small amounts of the anthrax toxin, the protein Protective Antigen A (PA), while the new vaccine contains only the protective antigen.

The vaccine was tested in a single dose in rabbits, with control rabbits being given BioThrax and a further group being given the smallpox vaccination. The combination vaccine protected 33 percent of the rabbits, while only around 10 percent were protected by BioThrax. The vaccine has also been tested on mice and found to be faster-acting than the alternative.

Side effects to smallpox and anthrax vaccines do occur, including severe allergic reactions and brain and heart inflammation, and anthrax vaccines must be given in multiple doses and have a shelf life of only four years. The can be stockpiled in a freeze-dried state and rapidly deployed in the event of a biological attack involving anthrax or smallpox.

According to Perera, the next stage in the research is to test the vaccine against anthrax in monkeys, and if this is successful human tests will follow. If testing is successful, the vaccine is likely to be ready for distribution within two or three years.

Both anthrax and smallpox are deadly diseases that can be turned into biological weapons. Having a single to protect against both, especially one that appears at this stage to work better than either of the single disease vaccines, would be highly advantageous in the aftermath of a bioterrorist attack.

The paper was published in the Proceedings of the National Academy of Sciences (PNAS) and the research was funded by the National Institutes of Health.

More information: Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities, Proceedings of the National Academy of Sciences, Published online before print October 4, 2010, doi:10.1073/pnas.1013083107

Related Stories

Recommended for you

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

bhiestand
not rated yet Oct 06, 2010
But will it remove the smallpox vaccine scar from my arm?

I kid, I kid, this is a great development if it passes muster. It'll be particularly useful for the military.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.